MicroRNA biomarkers are being extensively profiled as a potential diagnostic tool for the early assessment and prognosis of subclinical drug-induced cardiotoxicity in vulnerable patients.
Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs.
Sandhu et al. (Fri,) conducted a review in Cancer-therapy-induced cardiotoxicity. microRNA biomarkers was evaluated. MicroRNA biomarkers are being extensively profiled as a potential diagnostic tool for the early assessment and prognosis of subclinical drug-induced cardiotoxicity in vulnerable patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: